bioAffinity Technologies Inc

bioAffinity Technologies announced a 1-for-15 reverse stock split, effective at the opening of trading on the Nasdaq Capital Market, approved at the annual general meeting on April 30, 2026. The purpose is to restore NASDAQ’s minimum listing requirement; after the action approximately 592,373 issued and outstanding common shares will remain and fractional shares will be settled in cash. Exercise prices and share amounts of stock options, warrants and available volume under equity incentive plans will be adjusted proportionally; the CUSIP for the common stock will change to 09076W406. » Altro su de.investing.com

bioAffinity Technologies completed a private placement of pre-funded warrants to acquire 8,462,027 common shares and conducted the offering at-the-market. The combined effective price per pre-funded warrant plus two warrants is $0.4657; the pre-funded warrants have an exercise price of $0.007, the warrants have an initial exercise price of $0.4727 and expire after five years. The company expects gross proceeds of approximately $4.0 million before fees; WallachBeth Capital acted as sole placement agent. The securities were offered pursuant to Section 4(a)(2) and Regulation D and were not registered under the Securities Act; registration rights for the underlying shares will be granted. » Altro su de.investing.com

bioAffinity Technologies reports Q2 2026 sales growth for its lung cancer test CyPath Lung of over 200% versus the prior year and 30% versus Q1 2026. The number of ordering physician practices rose 155% versus Q2 2025; nearly 3,000 tests have been performed since market launch. Clinical data show a sensitivity of 92%, specificity of 87% and a negative predictive value of 99% in high‑risk patients. The company plans a large longitudinal study and development of additional diagnostics for asthma and COPD, but with a market capitalization of USD 3.66 million and a sharp share price decline it faces financial pressure; analysts do not expect profitability this year. » Altro su de.investing.com